Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
http://www.priceseries.com/trade/MCRB-Seres-Therapeutics-Inc-stock-gains-463-percent-a-Trade-Record-by-priceSeries-2020080420200904.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments